These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19555715)

  • 1. Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq.
    Weycker D; Sofrygin O; Kemner JE; Pelton SI; Oster G
    Vaccine; 2009 Aug; 27(36):4930-7. PubMed ID: 19555715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of childhood rotavirus vaccination in Taiwan.
    Wu CL; Yang YC; Huang LM; Chen KT
    Vaccine; 2009 Mar; 27(10):1492-9. PubMed ID: 19186200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France.
    Huet F; Largeron N; Trichard M; Miadi-Fargier H; Jasso-Mosqueda G
    Vaccine; 2007 Aug; 25(34):6348-58. PubMed ID: 17629598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
    De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
    Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the introduction of universal rotavirus vaccination in the Netherlands.
    Zomer TP; van Duynhoven YT; Mangen MJ; van der Maas NA; Vennema H; Boot H; de Melker HE
    Vaccine; 2008 Jul; 26(29-30):3757-64. PubMed ID: 18514975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
    Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
    Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands.
    Goossens LM; Standaert B; Hartwig N; Hövels AM; Al MJ
    Vaccine; 2008 Feb; 26(8):1118-27. PubMed ID: 18215445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
    Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
    Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?
    Mangen MJ; van Duynhoven YT; Vennema H; van Pelt W; Havelaar AH; de Melker HE
    Vaccine; 2010 Mar; 28(14):2624-35. PubMed ID: 20109593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.
    Fisman DN; Chan CH; Lowcock E; Naus M; Lee V
    Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.
    Jit M; Edmunds WJ
    Vaccine; 2007 May; 25(20):3971-9. PubMed ID: 17400341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
    Abbott C; Tiede B; Armah G; Mahmoud A
    Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comment on the contribution by Weycker et al., "Cost of routine immunization of young children against rotavirus infection with Rotarix ® versus RotaTeq ®".
    Toumi M; Vesikari T; Giaquinto C
    Vaccine; 2010 Oct; 28(45):7241; author reply 7242. PubMed ID: 20831915
    [No Abstract]   [Full Text] [Related]  

  • 15. Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium.
    Dhont P; Trichard M; Largeron N; Rafia R; Bénard S
    J Med Econ; 2008; 11(3):431-48. PubMed ID: 19450097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public health impact of accelerated immunization against rotavirus infection among children aged less than 6 months in the United States.
    Weycker D; Atwood MA; Standaert B; Krishnarajah G
    Hum Vaccin Immunother; 2014; 10(7):2032-8. PubMed ID: 25424813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
    Bilcke J; Van Damme P; Beutels P
    Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic analysis of rotavirus vaccination in Italy.
    Giammanco MD; Coniglio MA; Pignato S; Giammanco G
    Vaccine; 2009 Jun; 27(29):3904-11. PubMed ID: 19446934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.
    Atkins KE; Shim E; Carroll S; Quilici S; Galvani AP
    Vaccine; 2012 Nov; 30(48):6766-76. PubMed ID: 23000223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Rotarix: an oral human rotavirus vaccine.
    O'Ryan M; Linhares AC
    Expert Rev Vaccines; 2009 Dec; 8(12):1627-41. PubMed ID: 19943758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.